Lee Rosebush

Medical Freedom, Compounding and Family. Chairman of the OFA trade association

[American Academy of Peptide Medicine @peptidemedicine]

On July 23rd and 24th, the FDA advisory committee will review seven peptide therapies for 503A compounding.

BPC-157. TB-500. KPV. MOTS-C. Emideltide (DSIP). Semax. Epitalon.

The outcome determines whether physicians and pharmacists keep the ability to compound these therapies safely for their patients.

Follow the hearing and take action.
🔗 in bio.

[Hims House @himshouse]

$HIMS

🚨 THE FDA PEPTIDES VOTE IS DAYS AWAY

Peptides insider @DrJesseMorse expects approval

We discuss the FDA briefing document recommending *against* the 7 peptides, what the odds of approval are for each of the peptides under review (including BPC-157) and why U.S.-made API could be a major advantage for $HIMS

01:37 - FDA briefing document
03:24 - Getting peptides back in front of the FDA
08:58 - Prescribing peptides back in 2017
12:42 - Peptides safety data
16:08 - BPC-157 deep-dive and odds for approval
22:56 - TB-500 deep-dive
26:15 - Approval odds for the other 5 peptides
31:02 - Peptide efficacy data
34:40 - FDA politics and final decisions
40:30 - Peptides market size
42:48 - Training the doctors
47:20 - Shipping hurdles and gray-market risk
53:25 - Why peptides could reshape healthcare

Not financial, legal, or medical advice

[American Academy of Peptide Medicine @peptidemedicine]

Nearly 1,900 Americans have spoken. The message is clear: protect safe access to compounded peptides.

Comments included 130+ self-identified clinicians and 483 people who shared the conditions they treat with compounded peptides.

On July 23–24, the FDA will review BPC-157, TB-500, KPV, MOTS-c, DSIP (Emideltide), Semax, and Epitalon for 503A compounding.

Public comments close July 22. Make your voice heard. 🔗 in bio.

[American Academy of Peptide Medicine @peptidemedicine]

A major decision about peptide access is approaching, and your voice matters.

On July 23–24, the FDA will review peptides for 503A compounding, a decision that could impact patient access, affordability, and regulated care.

Public comments close July 22, 2026. Share your experience and let the committee know what access to compounded peptides means to you.

Link in bio.

[American Academy of Peptide Medicine @peptidemedicine]

The future of peptide therapy is about to change. Are you paying attention?

On July 23–24, the FDA advisory committee votes on whether licensed pharmacies can continue compounding peptide therapies for patients. The outcome shapes whether physicians and pharmacists keep access to safe, regulated compounded peptides, or patients get pushed to an unregulated gray market.

Take action, submit a public comment before July 22nd. Your voice matters, link in bio.

[Brigham Buhler @ferrisbuhler81]

The committee votes July 23–24. Comments submitted by July 9 go directly to the FDA panel.

Your voice matters.
Submit your comment here 👉🏼 https://t.co/QRUHCAzwpw

[American Academy of Peptide Medicine @peptidemedicine]

On July 23-24, The FDA committee will review peptides nominated for the 503A compounding list. The outcome shapes whether physicians and pharmacists keep access to safe, regulated compounded peptides for their patients.

submit a public comment before July 22nd. link in bio.

[Lee Rosebush @LeeRosebush]

Honored to advise @peptidemedicine Government Advisory Board as we work to align pharmacy policy with patient needs at the federal level. Advocacy is a long game, and we’re in it.

[Lee Rosebush @LeeRosebush]

If you are truly interested in peptides, this is the book for you. This book provides you with the materials to be truly informed….What questions should you ask? What should your prescriber be thinking about? And, where is this all heading?

The future of medicine and pharmacy is bright

[Brigham Buhler @ferrisbuhler81]

You’ve seen the word “peptides” everywhere. But what are they, really?

The Peptide Revolution cuts through the noise, breaking down the science, the history, and why these molecules matter more than most people realize.

From insulin to GLP-1s, peptides have been transforming medicine for over a century. This book explains how they work, how to use them safely, and why access to them matters.

Book 👉🏼 https://t.co/MDBOwG6KzR

@MAHA_Action @LeeRosebush @tonylyonspub @ways2wellX @peptidemedicine

[Brigham Buhler @ferrisbuhler81]

You’ve seen the word “peptides” everywhere. But what are they, really?

The Peptide Revolution cuts through the noise, breaking down the science, the history, and why these molecules matter more than most people realize.

From insulin to GLP-1s, peptides have been transforming medicine for over a century. This book explains how they work, how to use them safely, and why access to them matters.

Book 👉🏼 https://t.co/MDBOwG6KzR

@MAHA_Action @LeeRosebush @tonylyonspub @ways2wellX @peptidemedicine

[Lee Rosebush @LeeRosebush]

Come listen in on the conversation surrounding peptides and the future of healthcare this afternoon.

[MAHA Action @MAHA_Action]

🚨 LIVE: MAHA™ Action Media Hub 🚨

 📅 Wednesday, July 8th at 4:00 PM ET — Streaming live on Zoom

Doctors, advocates, and thought leaders discuss American health, from problems in our medical research system to the food we eat, the medicine we take, and the policies behind it all.

- Tony Lyons @tonylyonspub
- Steve Bannon @Bannons_WarRoom
- Emily Kaplan @emilykaplanX
- Lee Rosebush @LeeRosebush
- Charles Eisenstein @ceisenstein
- Mary Holland, J.D. @maryhollandnyc
- Dr. Daniel Pompa @DrDanPompa
- Brandon Hoffman
- Dr. Eric Berg @dr_ericberg

You don't want to miss this one. 👀

[Lee Rosebush @LeeRosebush]

It wasn’t just food studies…

[Brigham Buhler @ferrisbuhler81]

Peptides aren’t going away, but safe, legal access matters.

The conversation is happening now. On July 21, the FDA will hold a public meeting, followed by its July 23–24 review of peptides for 503A compounding.

Stay informed as the process moves forward. @peptidemedicine

[Dr. Alex Tatem @DrAlexTatem]

Three weeks.

That's how long until the FDA votes on the future of seven peptides:

BPC-157. TB-500. KPV. MOTS-c. DSIP. Semax. Epitalon.

The internet is convinced the FDA already killed them.

It didn't.

In this video I break down what the FDA briefing documents actually say, why this hearing matters, why I may be testifying before the FDA, and how this decision could shape the future of physician-supervised peptide access.

If you want your voice heard, submit a public comment to the FDA before July 9. Every comment submitted before the deadline is included in the committee's briefing materials.

Take action here: https://t.co/SiP7Crhpdp

Proceed accordingly.

[Lee Rosebush @LeeRosebush]

The GLP-1 shortage debate exposed a bigger issue: the FDA’s process for declaring shortages “resolved” lacks transparency and accountability. We’re pushing for legislative reform to fix that.

[Brigham Buhler @ferrisbuhler81]

Your body already knows how to heal itself. Peptides just give it the signal to do it faster.

Recovery isn’t just for athletes,
It’s for anyone who wants to feel like themselves again.

[Lee Rosebush @LeeRosebush]

Time to celebrate 250 and where better to do it than in DC!

[Lee Rosebush @LeeRosebush]

“Our biggest fear is not that we are inadequate. Our deepest fear is that we are powerful beyond measure.”

This is just the start.

[American Academy of Peptide Medicine @peptidemedicine]

AAPM is advocating for Category 1 classification so patients can access compounded peptides legally, through licensed pharmacies, with a valid prescription and physician supervision.

Public comments to the FDA are now open. Your comment matters 🔗 in bio.

[American Academy of Peptide Medicine @peptidemedicine]

Swipe through to see what’s under review and why it matters for regulated patient access in the U.S.

Public comments are open now, submit by July 9, your comment will go directly to the FDA committee. sign up to watch the hearing live, link in bio.